aTYR PHARMA INC (ATYR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$10.0M
Cash & Equivalents
$12.5M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$53M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05892614 | Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Relate... | PHASE2 | Recruiting | 25 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-01 | 8-K | aTYR PHARMA INC (ATYR) (CIK 0001339970) - EX-99.1 | EDGAR |